Chinook Therapeutics, Inc.

Novartis Ag

Aduro Biotech Inc.

Sarah M McWhirter

Thomas W Dubensky, Jr

Laura Hix Glickman

David Braun Kanne

Leonard Sung

Justin Leong

George Edwin Katibah

Kelsey Gauthier

Chudi Obioma Ndubaku

Jeffrey McKenna

Stephen Canham

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2'-fluoro substituted, bis-3&#x2032;,5&#x2032; CDNs, and most preferably one or more 2&#x2032;,2&#x2033;-diF-Rp,Rp, bis-3&#x2032;,5&#x2032;CDNs.

Compositions and methods for activating 'stimulator of interferon gene'13 dependent signalling

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2'- or 3&#x2032;-mono-fluoro substituted, or 2&#x2032;3&#x2032;-di-fluoro substituted mixed linkage 2&#x2032;,5&#x2032;-3&#x2032;,5&#x2032; CDNs.

Compositions and methods for activating 'stimulator of interferon gene'-dependent signalling

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2'-fluoro substituted, bis-3&#x2032;,5&#x2032;CDNs, and most preferably one or more 2&#x2032;,2&#x2033;-diF-Rp,Rp, bis-3&#x2032;,5&#x2032;CDNs.

Compositions and methods for activating 'stimulator of interferon gene'&#x2014;dependent signalling

Growing community of inventors

Albany, CA, United States of America

Sarah M McWhirter